Changes in Intrathoracic Impedance During Sacubitril/Valsartan Treatment

Heart Failure With Reduced Ejection Fraction Clinical Trial

— CHILISALT  

Official title:

Changes in Intrathoracic Impedance During Sacubitril/Valsartan Treatment: CHILISALT Study

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT03359967
• Other study ID #: CH1HF
• Status: Not yet recruiting
• Phase: N/A
• First received: November 27, 2017
• Last updated: November 30, 2017
• Start date: February 12, 2018
• Est. completion date: August 31, 2018

Study information

• Verified date: November 2017
• Source: Central Hospital, Izmir
• Contact: Ugur O Turk, Assoc. Prof. FESC, ECDS
• Phone: +905067021021
• Email: droturk[@]yahoo.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The CHILISALT Study aimed to explore the effect of angiotensin-neprilysin inhibition on intrathoracic impedance and -derived fluid index in HFrEF patients who had a device for cardiac resynchronization therapy and/or an implantable cardioverter-defibrillator (ICD; Medtronic Inc., Minneapolis, MN) allowing continuous measurement of intrathoracic impedance.

Description:

Background Cardiac implantable electronic devices (CIEDs) that are improving clinical outcomes in selected heart failure with reduced ejection fraction (HFrEF) patients also collect valuable diagnostic information from continuous monitoring of several physiological variables such as intrathoracic electrical impedance. Intrathoracic electrical impedance monitoring has been used as a tool to evaluate pulmonary congestion. Intrathoracic impedance is inversely correlated to pulmonary volume expansion and has been linked to cardiac filling pressures. Decreasing in intrathoracic impedance and -derived fluid indices such as OptiVol Fluid Index, has been shown to predict heart failure hospitalizations and all-cause mortality in patients with HFrEF. Furthermore, studies also have shown the usefulness of monitoring impedance to initiate timely interventions preventing decompensation.

In patients with symptomatic HFrEF, the PARADIGM-HF trial demonstrated that sacubitril/valsartan significantly reduced the primary endpoint of cardiovascular mortality and heart failure hospitalization, compared with enalapril. The rate of all-cause mortality was also significantly reduced. Subsequently, Sacubitril/Valsartan is recommended by current guidelines as foundational therapy for many patients with symptomatic HFrEF.

However as a natriuretic agent, effects of Sacubitril/Valsartan treatment on intrathoracic impedance and fluid index remains unclear.

Objective The CHILISALT Study aimed to explore the effect of angiotensin-neprilysin inhibition on intrathoracic impedance and fluid index values in HFrEF patients who were implanted with a device for cardiac resynchronization therapy and/or an implantable cardioverter-defibrillator (ICD; Medtronic Inc., Minneapolis, MN) allowing continuous measurement of intrathoracic impedance and OptiVol Fluid Index. Main outcome parameters are the change in intrathoracic impedanceand OptiVol Index values between baseline (before Sacubutril/Valsartan treatment) and, 14th and 28th days of Sacubutril/Valsartan treatment.

Material and Methods CHILISALT Study will designed as national, multicentre, non-interventional, observational, single arm cohort study. Study population will identified from dedicated CIED Clinics from participating centres. Patients will eligible if they had already taking Sacubitril/Valsartan for ≥2 weeks and had been implanted with CIED for ≥3 months. Additionally, eligible patients must have a CIED before Sacubitril/Valsartan prescription date. Due to descriptive (proof of mechanism) design of the CHILISALT Study a formal population volume calculation will not be made. However, after minimum 24 patients included an interim analysis will be done in terms of changes in impedance values and other related parameters between baseline and after Sacubitril/Valsartan treatment. An independent data monitoring committee will decide to enrol or to finalize the study according to main outcome variable distribution. Main outcome parameters are the change in intrathoracic impedance and OptiVol Fluid index values between baseline (before Sacubutril/Valsartan treatment) and, 14th and 28th days of Sacubutril/Valsartan treatment. As a tool to evaluate pulmonary fluid status, intrathoracic impedance measuring quantifies impedance changes. CIEDs measured intrathoracic impedance (ohms) using the RV-coil to can vector. Impedance-derived fluid index will obtained using a cumulative sum mathematical model that calculates the differences between impedance measured in ohms (measured impedance) and a reference impedance. OptiVol Fluid index will be expressed in ohm-days. It was demonstrated that the index value exceeded 60 ohm-days, the crossing of this threshold value predicted both increased morbidity and mortality. Other possible confounders such as change in body weight (kilogram), current diuretic dose (miligram per day), requirement of intravenous diuretic therapy (yes/no), and the change from baseline to 28th day of the treatment in the clinical summary score on the Kansas City Cardiomyopathy Questionnaire (KCCQ; on a scale from 0 to 100, with higher scores indicating fewer symptoms and physical limitations associated with heart failure) is selected as secondary outcomes.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 24
• Est. completion date: August 31, 2018
• Est. primary completion date: June 29, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

Patients will eligible if they had already taking Sacubitril/Valsartan for =2 weeks and had been implanted with CIED for =3 months. Additionally, eligible patients must have a CIED before Sacubitril/Valsartan prescription date.

Exclusion Criteria:

• Patients younger than 18 years.

• Patients who not taking or taking <2 weeks Sacubitril Valsartan

• Patients who had a CIED which not using OptiVol algoritm for impedance measurement.

• Patients with structural pulmonary disease

• Patients with obstructive sleep apnea syndrome who using a continuous positive airway pressure device

• Patients with CIED pocket abcess

Related Conditions & MeSH terms

• Heart Failure
• Heart Failure With Reduced Ejection Fraction

Intervention

Drug:
• Entresto tablet
Changes in intrathoracic impedance and other related parameters between before- and after Sacubitril/Valsartan treatment collected via previously implanted device algoritm. (OptiVol Fluid Index)

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Central Hospital, Izmir

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in intrathoracic impedance values (ohms) between baseline and 14th and 28th days of Sacubutril/Valsartan treatment	Main outcome parameter is the change in intrathoracic impedance values (ohms) measuring with a CIED using its RV-coil to can vector between baseline (before Sacubutril/Valsartan treatment) and, 14th and 28th days of Sacubutril/Valsartan treatment. (Baseline value minus 14th day value) (Baseline Value minus 28 th day value) (Ohms) ( Decreasing in intrathoracic impedance has been shown to predict heart failure hospitalizations and all-cause mortality in patients with HFrEF.	Baseline (1st day), 14 th day and 28th day. (Screening=-10 to -1 day, Enrollment (Baseline Visit), Visit 1 (14+/-2 days), Visit 2 (28+/-4 days)
Primary	Change in OptiVol Index Values (ohm-days) between baseline and 14th and 28th days of Sacubutril/Valsartan treatment.	Change in Optivol Index values (ohm-days) measuring with a CIED using its RV-coil to can vector between baseline (before Sacubutril/Valsartan treatment) and, 14th and 28th days of Sacubutril/Valsartan treatment. (Baseline value minus 14th day value) (Baseline Value minus 28 th day value) (Ohm-days) Decreasing in intrathoracic impedance derived fluid indices such as OptiVol Fluid Index, has been shown to predict heart failure hospitalizations and all-cause mortality in patients with HFrEF.	Baseline, 14th and 28th days of Sacubitril/Valsartan treatment
Secondary	Change in body weight (kilogram)	Differences in Morning Body weight (kilogram) at fasting state between baseline and 14 th, 28 th days of Sacubitril/Valsartan treatment.	Baseline, 14 th day and 28 th day
Secondary	Change in cumulative diuretic dose (miligram per day)	Changing of personal, current cumulative diuretic dose ( Between baseline and 14 th, 28 th days of Sacubitril/Valsartan treatment)	Baseline, 14 th day, and 28 th day
Secondary	Requirement of intravenous diuretic therapy	Requirement of intravenous a loop diuretic due to congestive status (inpatient and/or outpatient) (Admission times)	Baseline, 14 th day, and 28 th day
Secondary	Change in the clinical summary score on the Kansas City Cardiomyopathy Questionnaire (KCCQ).	Change from baseline to 28th day of the treatment in the clinical summary score on the Kansas City Cardiomyopathy Questionnaire (KCCQ) (on a scale from 0 to 100, with higher scores indicating fewer symptoms and physical limitations associated with heart failure)	Baseline, 28 th day